NTHI NeOnc Technologies Holdings Inc.

Execution in biotech doesn’t happen on one front. Recent progress at $NTHI has included positive NEO100 Phase 2a results, completion of NEO212 Phase 1 dose escalation, a $15M financing, and the elimination of potential dilution associated with its Series A Preferred Stock. Now, the appointment of Ali Alabedin adds decades of financial governance and international growth experience at the Board level. Clinical. Regulatory. Financial. Institutional. Different areas, one focus: building the capabilities to move the pipeline forward. $NTHI $RXRX $ABCL

Potential gets attention. Execution is what moves a company forward. $NTHI has been building across multiple fronts: positive NEO100 Phase 2a results, completion of NEO212 Phase 1 dose escalation, a $15M financing, and the cash redemption of its Series A Preferred Stock with no common shares issued. With both clinical programs moving toward their next regulatory steps, the story is increasingly about turning scientific potential into execution. $NTHI $IOVA $NVAX

NEO212 enters its next regulatory milestone with Phase 1 dose escalation completed and 610 mg selected as the recommended Phase 2 dose. Clinical observations reported to date include approximately 60% tumor reduction followed by 21 months of disease control in one recurrent GBM patient, and approximately 16 months of stable disease in a patient with brain metastases. While individual cases do not establish efficacy, these observations provide important clinical context as we prepare for the November 17 FDA meeting and the next stage of NEO212’s development. $NTHI $NVAX $RXRX

$NTHI — NeOnc has several things happening at once. NEO100 produced positive Phase 2a results in recurrent malignant glioma, management recently raised $15M, and the company has now scheduled an FDA End-of-Phase 1 meeting for NEO212. That FDA discussion should help determine the next clinical-development steps

$NTHI Why aren’t more people excited a iut this comoany and their ip oming meeting witrh the FDA on November 17? All indicarions are that the company has groundbreaking treatment for brain cancer and the only worry, albeit a big ine, is future financing

$NTHI secures boardroom firepower with new director appointment and redeems Series A preferred.

$NTHI reported encouraging Phase 2a survival data for intranasal NEO100 in recurrent high-grade glioma, showing median OS of 26.1 months.